key: cord-0785118-2mmeaolg
authors: Cabanillas, Beatriz; Novak, Natalija
title: Allergy to COVID-19 vaccines: a current update
date: 2021-04-23
journal: Allergol Int
DOI: 10.1016/j.alit.2021.04.003
sha: 8e203f54591b54e0a7d021af8febd237c3c296f2
doc_id: 785118
cord_uid: 2mmeaolg

Adverse allergic reactions due to the administration of the vaccines developed for the protection of coronavirus disease 2019 (COVID-19) have been reported since the initiation of the vaccination campaigns. Current analyses provided by the Center for Disease Control and Prevention (CDC) and Food and Drug Administration (FDA) in the United States have estimated the rates of anaphylactic reactions in 2.5 and 11.1 per million of mRNA-1273 and BNT162b2 vaccines administered, respectively. Although rather low, such rates could have importance due to the uncommon fact that a large majority of the world population will be subjected to vaccination with the aforementioned vaccines in the following months and vaccination will most likely be necessary every season as for influenza vaccines. Health regulators have advised that any subject with a previous history of allergy to drugs or any component of the vaccines should not be vaccinated, however, certain misunderstanding exists since allergy to specific excipients in drugs and vaccines are in occasions misdiagnosed due to an absence of suspicion to specific excipients as allergenic triggers or due to inaccurate labeling or nomenclature. In this review, we provide an updated revision of the most current data regarding the anaphylactic reactions described for BNT162b2 vaccine, mRNA-1273 vaccine, and AZD1222 vaccine. We extensively describe the different excipients in the vaccines with the potential to elicit systemic allergic reactions such as polyethylene glycol (PEG), polysorbates, tromethamine/trometamol, and others and the possible immunological mechanisms involved.

BNT162b2 vaccines administered, respectively. Although rather low, such rates could have 32 importance due to the uncommon fact that a large majority of the world population will be 33 subjected to vaccination with the aforementioned vaccines in the following months and 34 vaccination will most likely be necessary every season as for influenza vaccines. Health 35 regulators have advised that any subject with a previous history of allergy to drugs or any 36 component of the vaccines should not be vaccinated, however, certain misunderstanding 37 exists since allergy to specific excipients in drugs and vaccines are in occasions misdiagnosed 38 due to an absence of suspicion to specific excipients as allergenic triggers or due to inaccurate 39 labeling or nomenclature. In this review, we provide an updated revision of the most current 40 data regarding the anaphylactic reactions described for BNT162b2 vaccine, mRNA-1273 41 vaccine, and AZD1222 vaccine. We extensively describe the different excipients in the 42 vaccines with the potential to elicit systemic allergic reactions such as polyethylene glycol 43 (PEG), polysorbates, tromethamine/trometamol, and others and the possible immunological 44 mechanisms involved. 45

Introduction 52 J o u r n a l P r e -p r o o f Allergic reactions to routine vaccines have been estimated to affect 1-10 per 1,000,000 53 administrated doses. The reactions may be caused by excipients that act as preservatives, 54 stabilizers, or adjuvants. In that respect, excipients such as gelatine, ovalbumin from egg, 55 chicken proteins or cow's milk proteins, that can be found in vaccines such as mumps, 56 measles, rubella (MMR) vaccine, influenza vaccine, rabies vaccine, etc, have been described 57 to be responsible for allergic reactions. Antigens from the infectious agent of the vaccine can 58 also trigger allergic reactions but to a lesser extent (Wood, 2013; Nilsson et al., 2017) . 1 Therapeutics has also received emergency authorizations for its use in UK, USA, or EU. The 67 third vaccine for COVID-19 protection is a DNA vaccine, named as AZD1222 (produced by 68

AstraZeneca-Oxford University), and is the last one to receive approval by MHRA in the UK 69 and it is starting to be authorized by other regulatory agencies around the world. The 70 authorizations of the vaccines were based on the results of phase-III-trials involving 44,000 71 participants for the BNT162b2 vaccine trial and 30,000 participants for the mRNA-1273 72 vaccine trial, showing that these mRNA vaccines were 95% and 94.1% effective, 73 respectively, administrated in two dose-regimes 3-4 (Table 1 ). In the case of the AZD1222 74 vaccine, the approval was given after an interim analysis of the data pooled from four ongoing 75 phase I/II/III trials carried out in the UK, Brazil, and South Africa. The clinical trials involved 76 over 23,000 participants who were randomized 1:1 to receive AZD1222 or placebo. The 77 analysis showed that the vaccine efficacy was 62.1 % after two standard doses containing 5 x 78 J o u r n a l P r e -p r o o f 10 10 viral particles per dose. In a subset of subjects of the UK trial who received a first low 79 dose (half of the standard dose) followed by a standard dose, the efficacy of the vaccine 80 reached 90.0 % 5 (Table 1) . 81

The mRNA vaccines BNT162b2 and mRNA-1273 are based on the same technology of 82 mRNA that encodes the viral spike (S) glycoprotein of SARS-CoV-2. The mRNA molecule 83 in these vaccines is surrounded by lipid nanoparticles (LNPs) to provide stability to the 84 mRNA molecules. The LNPs have been additionally subjected to the chemical process of 85

PEGylation, which consists on the chemical attachment of polyethylene glycol (PEG) to the 86 surface of the LNPs in order to increase its efficiency and delivery to the target cells 6 ( Table  87 1). The AZD1222 vaccine is also based on the expression of the glycoprotein spike (S) 88

antigen of SARS-CoV-2, but in this case, AZD1222 is a DNA vaccine that consists of a 89 chimpanzee adenovirus vector (ChAdOx1) which is replication-deficient containing the gene 90 of the glycoprotein spike (S) antigen of SARS-CoV-2. Although PEGylated LNPs or other 91 PEG components are not found among the excipients of the AZD1222 vaccine, it does 92 contain polyoxyethylene-80-sorbitan monooleate (Table 1) , also named polysorbate 80 or 93

Tween 80, which has structural similarities with PEG ( Fig. 1) . 94

Soon after the initiation of the vaccination with the mRNA vaccines in December 2020, 95 adverse allergic reactions were started to be reported and the list of excipients of the vaccines 96 was subjected to an analysis by the scientific community in order to define the potential 97 culprits of the reactions. Although health authorities from different countries warned from the 98 beginning that any subject allergic to any component of the vaccines should not be 99 vaccinated, such advice was sometimes difficult to attain, since allergy to vaccine excipients 100 are in occasions misdiagnosed due to an absence of suspicion to specific excipients as 101 allergenic triggers or due to inaccurate labeling or nomenclature. Brighton Collaboration case definition criteria, 21 cases of anaphylaxis were found, which 116 results in 11.1 anaphylactic cases per million vaccine doses (Table 2) . Still, ten additional 117 cases were either under review or had insufficient information to be cataloged as anaphylaxis. (Table 2 ). Yet, 47 additional cases were cataloged as allergic reactions to the 131 vaccine although they were not anaphylactic reactions. The anaphylactic reactions occurred in 132 a median of 7.5 minutes (range 1 -45 minutes) and no deaths were reported. Six patients out 133 of 10 required hospitalizations including four patients that were subjected to endotracheal 134 intubation. Previous histories of allergic reactions, including drugs and contrast media, were 135 described in most of the patients (90 %), with previous anaphylaxis episodes in 5 out of 9 136 patients, including anaphylaxis to contrast media in two patients. 8 137 A robust female predominance in the anaphylactic reactions was found for both mRNA-1273 138 and BNT162b2 vaccines (100% for mRNA-1273 vaccine and 90% for BNT162b2 vaccine). 139

Although the vaccines were administrated to a higher percentage of women than men at the 140 PEGs or macrogols are hydrophilic polymers derived from ethylene oxide that are extensively 158 used as ingredients in medicaments, cosmetics, pharmaceutical, and food products ( Fig. 3) . 159

PEGs can be covalently linked to certain drugs, a method called PEGylation, in order to 160 enhance their molecular weight (MW), to protect the drug from degradation, and to increase 161 their circulation and delivery to target body compartments. 

An individual threshold of sensitization to PEG depending on its MW and its concentration 208 seems to exist. As mentioned before, the MW of PEGs can vary from 200 to 35,000 g/mol, in 209 that respect, some patients react to PEG-20000 (g/mol) but tolerate PEG-6000 (g/mol), or 210 cases of sensitization to PEG-3350 (g/mol) who are tolerant to PEG-300 (g/mol). 15,17,18 A case 211 has also been described for a subject with a previous history of anaphylaxis to PEG-3350 that 212 experienced later an anaphylactic reaction to PEGylated liposomes. 19 For that reason, it is 213 recommended that the MW of the PEG product contained in the index medicament causing 214 the reaction is included in the history as part of the diagnostic procedure to try to establish an 215 individual MW threshold for PEG sensitization. indicates the total numbers of ethylene oxide groups (-OCH 2 CH 2 ) in the molecule (Fig. 1) . 231

Polysorbates can also be found as an excipient in certain vaccines such as Hepatitis B vaccine, 232 influenza vaccine, or Human papillomavirus vaccine. The function is to contribute to the 233 J o u r n a l P r e -p r o o f solubility of the vaccine. 22 AZD1222 DNA vaccine contains polysorbate 80 among its 234 excipients ( Fig. 2) . Other vaccines for COVID-19 protection that use adenovirus vectors or 235 are based on the recombinant glycoprotein (S) spike antigen and that they are currently in 236 phases I, II, or III trials, also contain polysorbates 80 and 20. 10 The majority of the described 237 cases of allergic reactions to polysorbates has been linked to medicines that contain this 238 excipient. 23,24 However, allergy to vaccines due to polysorbates has been reported to a lesser 239 extent. 14,25 Similarly, to PEG, due to the general unawareness of the allergenic potential of 240 polysorbates, the cases of allergy to this compound that may be behind a hypersensitivity 241 reaction to a vaccine, may be underrepresented. 242

Cross-reactivity between polysorbates and PEG due to shared structures such as (-OCH 2 CH 2 ) 243 or -(OCH 2 CH 2 )OH has been described (Fig. 1) . In the CDC report of BNT162b2 vaccine, 2 244 out 21 patients with reported anaphylaxis to the BNT162b2 vaccine had past histories of 245 anaphylaxis to vaccines such as influenza (H1N1) or rabies vaccine. 7 Although PEG-2000 is 246 an excipient that has been first utilized in BNT162b2 and mRNA-1273 vaccines, 247 polysorbates, are frequently used in vaccines such as the ones used for influenza protection. 18 248 Therefore, patients sensitized to polysorbates could potentially react to PEG of specific 249 molecular weights if they are exposed to it at specific routes, such as intramuscularly. CDC 250 reports on the anaphylactic reactions to polysorbate containing COVID-19 vaccines, such as 251 AZD1222 DNA vaccine have not been released so far. 252 253

Tromethamine (C 4 H 11 NO 3 ) is an excipient that can be found in the mRNA-1273 vaccine but 255 not in the other two COVID-19 vaccines ( Fig. 2) . Tromethamine (or Trometamol) is an 256 organic amine proton acceptor that is used as a biological buffer in drugs for topical, enteral, 257 or parenteral application. It is also found in cosmetics as an emulsifier. Allergic sensitization 258 through contact due to trometamol-containing products has been described. 26 Trometamol is 259 J o u r n a l P r e -p r o o f also a common excipient in some contrast agents such as iodinated contrast medium (IOM) or 260 gadolinium-based contrast agents (GBCA). The risk of allergic reactions to GBCA increases 261 when a previous history of hypersensitivity to IOM exists. 27,28 However, an IgE cross-262 reactivity between both agents is unlikely since GBCAs and IOM are not structurally related. 263

In that sense, allergic reactions to these agents are sometimes suspected to be caused by 264 common excipients contained on them. In line with this assumption, recently an anaphylactic 265 reaction to GBCA due to the component trometamol in its formulation has been reported. 266

The anaphylactic reaction was described in a 23-year-old woman without previous history of 267 allergy to drugs that was exposed to GBCA through injection. The intradermal tests (IDT) 268 proved to be positive to the index GBCA, as well as an additional GBCA that contained 269 trometamol, however, it was negative to GBCA without trometamol in its formulation in IDT. However, the role of these compounds in the allergic reactions described to COVID-19 292 vaccines, if they have any, could be more limited than the main excipients that have been 293 described in the previous sections, attending to the limited scientific literature of previously 294 described cases with these compounds. 295

296

The mechanisms of the allergic reactions to PEG, polysorbates, tromethamine/trometamol, 298 and other vaccine components might be IgE-mediated, but also non mediated by IgE. In the 299 former, there is a recognition of the allergen by specific IgE molecules positioned on the high-300 affinity receptors for IgE (FcɛRI) on mast cells and basophils. Upon cross-linking, a release of 301 mediators such as histamine, prostaglandins, leukotrienes, tryptase, proteases, serotonin, etc, 302 is produced. Such mediators are involved in the symptomatology of allergy reactions, which 303 may include pruritus, erythema, rashes, angioedema, coughing, wheezing, hypotension, 304 gastrointestinal symptoms which may lead to a fatal outcome. 32 In the case of allergy non-305 mediated by IgE, the clinical symptoms resemble IgE-mediated allergy, but in this case, the 306 mechanisms do not involve IgE and may comprise the activation of complement in the so-307 called complement activation-related pseudoallergy (CARPA), or direct, non-IgE-mediated 308 activation of mast cells, among other mechanisms. In CARPA there is an induction of the 309 complement products C3a, C4a, C5a called anaphylatoxins that are disseminated in the 310 bloodstream and can act as cardiovascular autonomic organ regulators. 33 311

The European Academy of Allergy and Clinical Immunology (EAACI) has stated that unless 313 there is a history of allergic reactions to any component of the COVID-19 vaccines, there is 314 no contraindication for their administration. In that respect, a previous history of allergy to 315 foods, aeroallergens, or insect venoms is not a contraindication for the vaccines 316 administration. 34 Table 1 . Characteristics, components, and clinical trials of the vaccines BNT162b2, mRNA-1273, and AZD1222 for COVID-19 prevention 

Allergic reactions to vaccines

Vaccination and 341 allergy: EAACI position paper, practical aspects

Safety and 343 efficacy of the BNT162b2 mRNA Covid-19 vaccine

Efficacy and safety 345 of the mRNA-1273 SARS-CoV-2 vaccine

Safety 347 and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an 348 interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. 349

PEGylation as a strategy for improving 351 nanoparticle-based drug and gene delivery

CDC COVID-19 Response Team, Administration FaD. Allergic Reactions Including 353

Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine -354

United States

CDC COVID-19 Response Team, Administration FaD. Allergic Reactions Including 356

Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine -United States

Allergic reactions to the first COVID-19 vaccine: a 359 potential role of Polyethylene glycol? Allergy

Maintaining safety with SARS-CoV-2 vaccines

PEGylation, successful approach to drug delivery

PEGylation of biopharmaceuticals: A 365 review of chemistry and nonclinical safety information of approved drugs

Immediate-type hypersensitivity to polyethylene glycols: a 368 review

Immediate 370 hypersensitivity to polyethylene glycols and polysorbates: More common than we have 371 recognized

Polyethylene glycol-induced systemic allergic reactions 373 (anaphylaxis)

Anti-PEG IgE in 375 anaphylaxis associated with polyethylene glycol

COVID-19 vaccine anaphylaxis: IgE, complement or 378 what else? A reply to

COVID-19 vaccine anaphylaxis: PEG or not? 381 Allergy 2021

Anaphylaxis to PEGylated liposomal 383 echocardiogram contrast in a patient with IgE-mediated macrogol allergy

Immediate hypersensitivity reactions to steroids 386 and steroid containing medications

Basics of 388 pharmaceutical emulsions: A review

Evaluation of a 390 sensitive GC-MS method to detect polysorbate 80 in vaccine preparation

Xolair-induced recurrent 393 anaphylaxis through sensitization to the excipient polysorbate

Anaphylaxis due to the excipient polysorbate 80

Hypersensitivity reaction to human papillomavirus 399 vaccine due to polysorbate 80

Contact sensitivity to octyldodecanol and 401 trometamol in an anti-itch cream

Adverse reactions to gadolinium contrast media: a 403 review of 36 cases

Lufkin RB. Severe anaphylactoid reaction to Gd-DTPA

Anaphylaxis 406 to trometamol excipient in gadolinium-based contrast agents for clinical imaging

Other excipients than PEG might cause serious 409 hypersensitivity reactions in COVID-19 vaccines

Systemic allergy to EDTA in 411 local anesthetic and radiocontrast media

Mechanisms of drug-induced allergy

Complement activation-related pseudoallergy: a stress reaction in blood 415 triggered by nanomedicines and biologicals

EAACI 417 statement on the diagnosis, management and prevention of severe allergic reactions to 418 COVID-19 vaccines